In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...